TG Therapeutics Is Worth A Look Before Phase 3 Combination Cancer Data [Seeking Alpha]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Seeking Alpha
Summary TG Therapeutics expects to report phase 3 cancer data next month from its study using TG-1101 (ublituximab) and TGR-1202 (umbralisib) to treat patients with first-line r/r chronic lymphocytic leukemia. A phase 2 study proved that TGR-1202 as a monotherapy only had 13% discontinuation rate as opposed to other BTK inhibitors and PI3K deltas that had 40% or more. The opportunity for TG Therapeutics is massive because the ability to go after both front-line r/r CLL and NHL could net billions in revenue. The company has $126.3 million in cash as of June 30, 2018, which means it has enough funds to run its operations into the second half of 2019. TG Therapeutics (NASDAQ: TGTX ) might be worth a speculative buy because it will release data from its phase 3 cancer study, which is approaching quickly. If the results are positive, then it will be able to file for an FDA approval of its combination product TG-1101 (ublituximab) and TGR-1202 (umbralisib) to treat patients
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/28/24 - Beat
TGTX
Sec Filings
- 4/18/24 - Form PRE
- 3/15/24 - Form 4
- 3/13/24 - Form 4
- TGTX's page on the SEC website